Antidepressants may mitigate the effects of prenatal maternal anxiety on infant auditory sensory gating

American Journal of Psychiatry

Volumn 169, Issue 6, 2012, Pages 616-624

  Hunter, Sharon K ^a,b   Mendoza, Jordan H ^a,b   D'Anna, Kimberly ^a,b   Zerbe, Gary O ^a,b   McCarthy, Lizbeth ^a,b   Hoffman, Camille ^a,b   Freedman, Robert ^a,b   Ross, Randal G ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b DENVER HEALTH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CITALOPRAM; ESCITALOPRAM; FLUOXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADULT; ANXIETY DISORDER; ARTICLE; BRAIN FUNCTION; CONTROLLED STUDY; DEPRESSION; DRUG EFFECT; DSM-IV; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MATERNAL DISEASE; PERINATAL PERIOD; PRENATAL DRUG EXPOSURE; PRENATAL MATERNAL ANXIETY; PRENATAL PERIOD; PRIORITY JOURNAL; SENSORY GATING; SLEEP; STIMULUS RESPONSE; TREATMENT RESPONSE;

EID: 84862185042     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2012.11091365     Document Type: Article

References (76)

1. Alwan S, Reefhuis J, Rasmussen SA, Friedman JM; National Birth Defects Prevention Study: Patterns of antidepressant medication use among pregnant women in a United States population. J Clin Pharmacol 2011; 51:264-270
2. Cohen LS, Altshuler LL, Harlow BL, Nonacs R, Newport DJ, Viguera AC, Suri R, Burt VK, Hendrick V, Reminick AM, Loughead A, Vitonis AF, Stowe ZN: Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 2006; 295:499-507 (Pubitemid 43200344)
3. Yonkers KA, Wisner KL, Stewart DE, Oberlander TF, Dell DL, Stotland N, Ramin S, Chaudron L, Lockwood C: The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Gen Hosp Psychiatry 2009; 31:403-413
4. O'Connor TG, Heron J, Golding J, Beveridge M, Glover V: Maternal antenatal anxiety and children's behavioral/emotional problems at 4 years: report from the Avon Longitudinal Study of Parents and Children. Br J Psychiatry 2002; 180:502-508 (Pubitemid 34596800)
5. Huizink AC, Dick DM, Sihvola E, Pulkkinnen L, Rose RJ, Kaprio J: Chernobyl exposure as a stressor during pregnancy and behaviour in adolescent offspring. Acta Psychiatr Scand 2007; 116:438-446 (Pubitemid 350086141)
6. Van den Bergh BR, Van Calster B, Smits T, Van Huffel S, Lagae L: Antenatal maternal anxiety is related to HPA-axis dysregulation and self-reported depressive symptoms in adolescence: a prospective study on the fetal origins of depressed mood. Neuropsychopharmacology 2008; 33:536-545
7. Van den Bergh BR, Marcoen A: High antenatal maternal anxiety is related to ADHD symptoms, externalizing problems, and anxiety in 8- and 9-year-olds. Child Dev 2004; 75:4085-4097
8. Rodriguez A, Bohlin G: Are maternal smoking and stress during pregnancy related to ADHD symptoms in children? J Child Psychol Psychiatry 2005; 46:246-254
9. Halligan SL, Murray L, Martins C, Cooper PJ: Maternal depression and psychiatric outcomes in adolescent offspring: a 13-year longitudinal study. J Affect Disord 2007; 97:145-154 (Pubitemid 44940819)
10. Gutteling BM, de Weerth D, Zandbelt N, Mulder EJH, Viser GHA, Buitelaar JK: Does maternal prenatal stress adversely affect the child's learning and memory at age six? J Abnorm Child Psychol 2006; 34:789-798 (Pubitemid 44900131)
11. Laplante DP, Barr RG, Brunet A, Galbaud Du Fort G, Meaney ML, Saucier JF, Zelazo PR, King S: Stress during pregnancy affects general intellectual and language functioning in human toddlers. Pediatr Res 2004; 56:400-410 (Pubitemid 39128826)
12. Van den Bergh BRH, Mennes M, Oosterlaan J, Stevens V, Stiers P, Marcoen A, Lagae L: High antenatal maternal anxiety is related to impulsivity during performance on cognitive tasks in 14- and 15-year-olds. Neurosci Biobehav Rev 2005; 29:259-269 (Pubitemid 40461743)
13. Kinney DK, Miller AM, Crowley DJ, Huang E, Gerber E: Autism prevalence following prenatal exposure to hurricanes and tropical storms in Louisiana. J Autism Dev Disord 2008; 38:481-488 (Pubitemid 351322368)
14. Khashan AS, Abel KM, McNamee R, Pedersen MG, Webb RT, Baker PN, Kenny LC, Mortensen PB: Higher risk of offspring schizophrenia following antenatal maternal exposure to severe adverse life events. Arch Gen Psychiatry 2008; 65:146-152 (Pubitemid 351214313)
15. Oberlander TF, Gingrich JA, Ansorge MS: Sustained neurobehavioral effects of exposure to SSRI antidepressants during development: molecular to clinical evidence. Clin Pharmacol Ther 2009; 86:672-677
16. Gunlicks ML, Weissmann MM: Change in child psychopathology with improvement in parental depression: a systematic review. J Am Acad Child Adolesc Psychiatry 2008; 47:379-389 (Pubitemid 351450736)
17. Nakhai-Pour HR, Broy P, Bérard A: Use of antidepressants during pregnancy and the risk of spontaneous abortion. CMAJ 2010; 182:1031-1037
18. Wisner KL, Sit DK, Hanusa BH, Moses-Kolko EL, Bogen DL, Hunker DF, Perel JM, Jones-Ivy S, Bodnar LM, Singer LT: Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes. Am J Psychiatry 2009; 166:557-566
19. Toh S, Mitchell AA, Louik C, Werler MM, Chambers CD, Hernández- Díaz S: Antidepressant use during pregnancy and the risk of preterm delivery and fetal growth restriction. J Clin Psychopharmacol 2009; 29:555-560
20. Reis M, Källén B: Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med 2010; 40:1723-1733
21. Diav-Citrin O, Shechtman S, Weinbaum D, Wajnberg R, Avgil M, Di Gianantonio E, Clementi M, Weber-Schoendorfer C, Schaefer C, Ornoy A: Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study. Br J Clin Pharmacol 2008; 66:695-705
22. Bakker MK, Kerstjens-Frederikse WS, Buys CH, de Walle HE, de Jong-van den Berg LT: First-trimester use of paroxetine and congenital heart defects: a population-based case-control study. Birth Defects Res A Clin Mol Teratol 2010; 88:94-100
23. Casper RC, Fleisher BE, Lee-Ancajas JC, Gilles A, Gaylor E, DeBattista A, Hoyme HE: Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J Pediatr 2003; 142:402-408 (Pubitemid 36521227)
24. Murray L, Arteche A, Fearon P, Halligan S, Croudace T, Cooper P: The effects of maternal postnatal depression and child sex on academic performance at age 16 years: a developmental approach. J Child Psychol Psychiatry 2010; 51:1150-1159
25. Adler LE, Pachtman E, Franks R, Freedman R: Neurophysiological evidence for a defect in neuronal mechanisms involved in sensory gating in schizophrenia. Biol Psychiatry 1982; 17:639-654
26. Martin LF, Hall MH, Ross RG, Zerbe G, Freedman R, Olincy A: Physiology of schizophrenia, bipolar disorder, and schizoaffective disorder. Am J Psychiatry 2007; 164:1900-1906
27. Olincy A, Ross RG, Harris JG, Young DA, McAndrews MA, Cawthra E, McRae KA, Sullivan B, Adler LE, Freedman R: The P50 auditory event-evoked potential in adult attention-deficit disorder: comparison with schizophrenia. Biol Psychiatry 2000; 47:969-977 (Pubitemid 30320742)
28. Stewart LP, White PM: Sensory filtering phenomenology in PTSD. Depress Anxiety 2008; 25:38-45 (Pubitemid 351213923)
29. Ghisolfi ES, Margis R, Becker J, Zanardo AP, Strimitzer IM, Lara DR: Impaired P50 sensory gating in post-traumatic stress disorder secondary to urban violence. Int J Psychophysiol 2004; 51:209-214 (Pubitemid 38220934)
30. Neylan TC, Fletcher DJ, Lenoci M, McCallin K, Weiss DS, Schoenfeld FB, Marmar CR, Fein G: Sensory gating in chronic posttraumatic stress disorder: reduced auditory P50 suppression in combat veterans. Biol Psychiatry 1999; 46:1656-1664 (Pubitemid 30001608)
31. Gillete GM, Skinner RD, Rasco LM, Fielstein LM, Davis EM, Pawelak DH, Freeman JE, Karson TW, Boop CN, Garcia-Rill E: Combat veterans with posttraumatic stress disorder exhibit decreased habituation of the P1 midlatency auditory evoked potential. Life Sci 1997; 61:1421-1434 (Pubitemid 27394366)
32. Teo C, Rasco L, al-Mefty K, Skinner RD, Boop FA, Garcia-Rill E: Decreased habituation of midlatency auditory evoked responses in Parkinson's disease. Mov Disord 1997; 12:655-664 (Pubitemid 27406258)
33. Harris JG, Adler LE, Young DA, Cullum CM, Rilling LM, Cicerello A, Intemann PM, Freedman R: Neuropsychological dysfunction in parents of schizophrenics. Schizophr Res 1996; 20:253-260 (Pubitemid 26232969)
34. Cullum CM, Harris JG, Waldo MC, Smernoff E, Madison A, Nagamoto HT, Griffith J, Adler LE, Freedman R: Neurophysiological and neuropsychological evidence for attentional dysfunction in schizophrenia. Schizophr Res 1993; 10:131-141 (Pubitemid 23273366)
35. Kisley MA, Noecker TL, Guinther PM: Comparison of sensory gating to mismatch negativity and self-reported perceptual phenomena in healthy adults. Psychophysiology 2004; 41:604-612 (Pubitemid 38879775)
36. Kisley MA, Polk SD, Ross RG, Levisohn PM, Freedman R: Early postnatal development of sensory gating. Neuroreport 2003; 14:693-697 (Pubitemid 36570924)
37. Kisley MA, Olincy A, Freedman R: The effect of state on sensory gating: comparison of waking, REM, and non-REM sleep. Clin Neurophysiology 2001; 112:1154-1165 (Pubitemid 32539441)
38. Kisley MA, Olincy A, Robbins E, Polk SD, Adler LE, Waldo MC, Freedman R: Sensory gating impairment associated with schizophrenia persists into REM sleep. Psychophysiology 2003; 40:29-38 (Pubitemid 36168915)
39. Gillow S, Hunter S, Ross R: Stability of P50 sensory gating in preschoolers (abstract). J Investig Med 2010; 58:154-155
40. Hunter SK, Kisley MA, Freedman R, Ross RG: Diminished cerebral inhibition in neonates associated with risk factors for schizophrenia: parental psychosis, maternal depression, and nicotine use. Schizophr Bull 2011; 37:1200-1208
41. O'Connor TG, Heron J, Glover V; Alspac Study Team: Antenatal anxiety predicts child behavioral/emotional problems independently of postnatal depression. J Am Acad Child Adolesc Psychiatry 2002; 41:1470-1477 (Pubitemid 44698524)
42. Obel C, Hedegaard M, Henriksen TB, Secher NJ, Olsen J: Psychological factors in pregnancy and mixed-handedness in the offspring. Dev Med Child Neurol 2003; 45:557-561 (Pubitemid 36873973)
43. Glover V: Annual research review: prenatal stress and the origins of psychopathology: an evolutionary perspective. J Child Psychol Psychiatry 2011; 52:356-367
44. Herndon A, Hunter S, Ross R: How does auditory gating in newborns with prenatal drug and/or nicotine exposure differ from newborns with normal pattern exposures? (abstract). J Investig Med 2009; 57:98
45. First MB, Spitzer RL, Gibbon M, Williams JBW: Structured Clinical Interview for DSM-IV Axis I Disorders, Patient Edition. New York, New York State Psychiatric Institute, 1997
46. Hunter SK, Corral N, Ponicsan H, Ross RG: Reliability of P50 auditory sensory gating measures in infants during active sleep. Neuroreport 2008; 19:79-82 (Pubitemid 351339625)
47. Nakao K, Treas J: The 1989 Socioeconomic Index of Occupations: construction from the 1989 occupational prestige scores. General Social Survey Methodological Report No 74. Chicago, University of Chicago, National Opinion Research Center, May 1992
48. Clavarino AM, Mamun AA, O'Callaghan M, Aird R, Bor W, O'Callaghan F, Williams GM, Marrington S, Najman JM, Alati R: Maternal anxiety and attention problems in children at 5 and 14 years. J Atten Disord 2010; 13:658-667
49. Van den Bergh BRH, Marcoen A: High antenatal maternal anxiety is related to ADHD symptoms, externalizing problems, and anxiety in 8- and 9-year-olds. Child Dev 2004; 75:1085-1097
50. Scholtissen-In de Braek DM, Hurks PP, van Boxtel MP, Dijkstra JB, Jolles J: The identification of attention complaints in the general population and their effect on quality of life. J Atten Disord 2011; 15:46-55
51. Lahey BB, Van Hulle CA, Singh AL, Waldman ID, Rathouz PJ: Higher-order genetic and environmental structure of prevalent forms of child and adolescent psychopathology. Arch Gen Psychiatry 2011; 68:181-189
52. Larson K, Russ SA, Kahn RS, Halfon N: Patterns of comorbidity, functioning, and service use for US children with ADHD, 2007. Pediatrics 2011; 127:462-470
53. Pluess M, Bolten M, Pirke KM, Hellhammer D: Maternal trait anxiety, emotional distress, and salivary cortisol in pregnancy. Biol Psychology 2010; 83:169-175
54. Glover V, Bergman K, Sarkar P, O'Connor TG: Association between maternal and amniotic fluid cortisol is moderated by maternal anxiety. Psychoneuroendocrinology 2009; 34:430-435
55. Swerdlow NR, Hartman PL, Auerbach PP: Changes in sensorimotor inhibition across the menstrual cycle: implications for neuropsychiatric disorders. Biol Psychiatry 1997; 41:452-460 (Pubitemid 27087328)
56. Ross RG, Stevens KE, Proctor WR, Leonard S, Kisley MA, Hunter SK, Freedman R, Adams CE: Cholinergic mechanisms, early brain development, and risk for schizophrenia. J Child Psychol Psychiatry 2010; 51:535-549
57. Stevens KE, Freedman R, Collins AC, Hall M, Leonard S, Marks MJ, Rose GM: Genetic correlation of inhibitory gating of hippocampal auditory evoked response and alpha-bungarotoxin- binding nicotinic cholinergic receptors in inbred mouse strains. Neuropsychopharmacology 1996; 15:152-162 (Pubitemid 26255162)
58. Adams CE, Yoncheck JC, Zheng L, Collins AC, Stevens KE: Altered hippocampal circuit function in C3H alpha7 null mutant heterozygous mice. Brain Res 2008; 1194:138-145
59. Stevens K, Adams CE, Mellot TJ, Robbins E, Kisley MA: Perinatal choline deficiency produces abnormal sensory inhibition in Sprague-Dawley rats. Brain Res 2008; 1237:84-90
60. Ulus IH, Ozyurt G, Korfali E: Decreased serum choline concentrations in humans after surgery, childbirth, and traumatic head injury. Neurochem Res 1998; 23:727-732
61. Ilcol YO, Uncu G, Goren S, Sayan E, Ulus IH: Declines in serum free and bound choline concentrations in humans after three different types of major surgery. Clin Chem Lab Med 2004; 42:1390-1395
62. Ilcol YO, Uncu G, Ulus IH: Free and phospholipid-bound choline concentrations in serum during pregnancy, after delivery, and in newborns. Arch Physiol Biochem 2002; 110:393-399 (Pubitemid 35454399)
63. Ilcol YO, Ozyurt G, Kilicturgay S, Uncu G, Ulus IH: The decline in serum choline concentration in humans during and after surgery is associated with the elevation of cortisol, adrenocorticotropic hormone, prolactin, and beta-endorphin concentrations. Neruosci Lett 2002; 324:41-44 (Pubitemid 34442673)
64. Ilcol YO, Yilmaz Z, Ulus IH: Serum free and phospholipid-bound choline decrease and surgery and methylprednisolone administration in dogs. Neurosci Lett 2003; 339:195-198 (Pubitemid 36299000)
65. Olincy A, Martin L: Diminished suppression of the P50 auditory evoked potential in bipolar disorder subjects with a history of psychosis. Am J Psychiatry 2005; 162:43-49 (Pubitemid 40095671)
66. Wang Y, Fang YR, Chen XS, Chen J, Wu ZG, Yuan CM, Yi ZH, Hong W, Zhang C, Cao L: A follow-up study on featuers of sensory gating P50 in treatment-resistant depression patients. Chin Med J (Engl) 2009; 122:2956-2960
67. Fann AV, Preston MA, Bray P, Mamiya N, Williams DK, Skinner RD, Garcia-Rill E: The P50 midlatency auditory evoked potential in patients with chronic low back pain (CLBP). Clin Neurophysiol 2005; 116:681-689 (Pubitemid 40249835)
68. Wildeboer KM, Stevens KE: Stimulation of the [alpha]4[beta]2 nicotinic receptor by 5-I A-85380 improves auditory gating in DBA/2 mice. Brain Res 2008; 1224:29-36
69. Arias HR, Feuerbach D, Targowska-Duda KM, Russell M, Jozwiak K: Interaction of selective serotonin reuptake inhibitors with neuronal nicotinic acetylcholine receptors. Biochemistry 2010; 49:5734-5742
70. Arias HR, Rosenberg A, Targowska-Duda KM, Feuerbach D, Jozwiak K, Moaddel R, Wainer IW: Tricyclic antidepressants and mecamylamine bind to different sites in the human [alpha]4[beta]2 nicotinic receptor ion channel. Int J Biochem Cell Biol 2010; 42:1007-1018
71. Mayer A, Szasz BK, Kiss JP: Inhibitory effect of antidepressants on the NMDA-evoked [3H]noradrenaline release from rat hippocampal slices. Neurochem Int 2009; 55:383-388
72. Arias HR: Is the inhibition of nicotinic acetylcholine receptors by bupropion involved in its clinical actions? Int J Biochem Cell Biol 2009; 41:2098-2108
73. Mansvelder HD, Fagen ZM, Chang B, Mitchum R, McGehee DS: Bupropion inhibits the cellular effects of nicotine in the ventral tegmental area. Biochem Pharmacol 2007; 74:1283-1291 (Pubitemid 47417936)
74. Dwoskin LP, Rauhut AS, King-Pospisil KA, Bardo MT: Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent. CNS Drug Rev 2006; 12:178-207 (Pubitemid 46047787)
75. Lopez-Valdes HE, Garia-Colunga J, Miledi R: Effects of clomipramine on neuronal nicotinic acetylcholine receptors. Eur J Pharmacol 2002; 444:13-19 (Pubitemid 34621329)
76. Slemmer JE, Martin BR, Damaj MI: Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther 2000; 295:321-327